Dravet Syndrome clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    open to eligible people ages 2 years and up

    This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).

    Orange 5379513, California 5332921 and other locations

Last updated: